title: Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
abstract: This study is focused on therapy-related myeloid neoplasms after the most promising frontline FCR (fludarabine, cyclophosphamide, and rituximab) therapy in previously untreated chronic lymphocytic leukemia patients. A total of 28 therapy-related myeloid neoplasm patients were identified, including 19 patients from 3 well-controlled FCR frontline trials (n=426 patients), giving an estimated frequency of 4.5% (1.9-8.3%) in a follow-up period of 44 months (range 5-122 months). Clinically, therapy-related myeloid neoplasms could emerge directly from 'prolonged myelosuppression' after FCR (10 patients), or after achieving complete hematological recovery (n=18). The overall latency was 35 months (range 3-118 months), with the former group of 23 months and the latter 42 months (P<0.001). In all, 10 cases presented as therapy-related acute myeloid leukemia and 18 as therapy-related myelodysplastic syndromes. Abnormal cytogenetics was present in 26 of 27 (96%) patients, with frequent chromosomes 5 and 7 abnormalities. The median survival was 7 months after therapy-related myeloid neoplasms. Our results indicate that the risk of therapy-related myeloid neoplasms secondary to frontline FCR therapy may not be as high as previously reported after removing the confounding factor of previous cytotoxic exposure, but this risk increased with older age and likely growth factor co-administration. Therapy-related myeloid neoplasms after FCR therapy shares clinicopathological features with therapy-related myeloid neoplasms secondary to other alkylating agents, but has a shorter latency interval indicating possible synergetic effects of the nucleotide analog fludarabine. The fact that therapy-related myeloid neoplasms can directly emerge from 'prolonged myelosuppression' warrants a bone marrow examination to rule out therapy-related myeloid neoplasms in this clinical setting.
authors.affiliation: Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Yi
authors.initials: Y
authors.lastname: Zhou
authors.forename: Guilin
authors.initials: G
authors.lastname: Tang
authors.forename: L Jeffrey
authors.initials: LJ
authors.lastname: Medeiros
authors.forename: Timothy J
authors.initials: TJ
authors.lastname: McDonnell
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Keating
authors.forename: William G
authors.initials: WG
authors.lastname: Wierda
authors.forename: Sa A
authors.initials: SA
authors.lastname: Wang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015994:Incidence; D053208:Kaplan-Meier Estimate; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000453:epidemiology* / Q000401:mortality; D012189:Retrospective Studies; D000069283:Rituximab; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine
references.citation: Blood. 2005 Jun 15;105(12):4573-5
references.pmid: 15741224
references.citation: Leukemia. 2009 Feb;23(2):305-12
references.pmid: 18987661
references.citation: Ann Oncol. 2010 Feb;21(2):331-334
references.pmid: 19625344
references.citation: Blood. 2008 Jun 15;111(12):5446-56
references.pmid: 18216293
references.citation: Blood. 2000 Jul 15;96(2):429-36
references.pmid: 10887102
references.citation: Blood. 2003 Jul 1;102(1):43-52
references.pmid: 12623843
references.citation: J Clin Oncol. 2002 Sep 15;20(18):3878-84
references.pmid: 12228208
references.citation: Blood. 2001 Oct 15;98(8):2319-25
references.pmid: 11588025
references.citation: Blood. 2008 Aug 15;112(4):975-80
references.pmid: 18411418
references.citation: Cancer. 2009 Jan 1;115(1):101-6
references.pmid: 19090005
references.citation: Int J Hematol. 2010 Apr;91(3):530-3
references.pmid: 20155339
references.citation: Leuk Lymphoma. 2005 Jul;46(7):1051-5
references.pmid: 16019557
references.citation: Blood. 1998 Aug 15;92(4):1165-71
references.pmid: 9694704
references.citation: N Engl J Med. 2000 Dec 14;343(24):1750-7
references.pmid: 11114313
references.citation: Leuk Lymphoma. 2010 Nov;51(11):2120-5
references.pmid: 20846095
references.citation: J Clin Pathol. 2009 May;62(5):468-70
references.pmid: 19398596
references.citation: Leuk Res. 1992;16(2):123-31
references.pmid: 1545564
references.citation: Clin Cancer Res. 2001 Nov;7(11):3580-9
references.pmid: 11705880
references.citation: Blood. 2004 Feb 15;103(4):1222-8
references.pmid: 14576060
references.citation: Blood. 2010 Jun 24;115(25):5131-6
references.pmid: 20237318
references.citation: Am J Hematol. 2006 Jun;81(6):473
references.pmid: 16680754
references.citation: Leuk Res. 2009 Jul;33(7):1001-4
references.pmid: 19155067
references.citation: Leukemia. 2010 Dec;24(12):2056-62
references.pmid: 20962860
references.citation: Haematologica. 2006 Nov;91(11):1546-50
references.pmid: 17082012
references.citation: Br J Haematol. 2007 Mar;136(6):800-5
references.pmid: 17341265
references.citation: Leuk Res. 2008 Jan;32(1):199-200
references.pmid: 17870157
references.citation: J Clin Oncol. 2007 Sep 20;25(27):4285-92
references.pmid: 17709799
references.citation: Br J Haematol. 2006 Jul;134(2):242-3
references.pmid: 16846486
references.citation: Exp Hematol. 2009 Nov;37(11):1266-73
references.pmid: 19654036
references.citation: J Clin Oncol. 2005 Jun 20;23(18):4079-88
references.pmid: 15767648